AZD6423 SAD/MAD Study in Healthy Volunteers - AZD6423
Study identifier:D3521C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Randomized, Double-Blind, Third-Party-Unblinded, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of AZD6423 in Healthy Volunteers
Medical condition
Healthy Volunteers.
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD6423, Placebo
Sex
All
Actual Enrollment
175
Study type
Interventional
Age
N/A
Date
Study Start Date: 01 Sept 2013
Primary Completion Date: 01 Mar 2014
Study Completion Date: 01 Mar 2014
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verification:
Verified 01 Apr 2014 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: Experimental: AZD6423 Subjects will participate in 1 of 8 groups and receive single or multiple doses of AZD6423 or matching placebo. In each group 6 subjects will receive AZD6423 and 2 subjects will receive matching placebo. | Drug: AZD6423 Drug: AZD6423 Single or Multiple doses via infusion. |
| Placebo Comparator: Placebo to match AZD6423 Subjects will participate in 1 of 8 groups and receive single or multiple doses of AZD6423 or matching placebo. In each group 6 subjects will receive AZD6423 and 2 subjects will receive matching placebo. | Drug: Placebo Placebo to match AZD6423 Single or Multiple doses of matching placebo delivered via infusion |
Contacts
Investigators
Principal Investigator
David Han
California Clinical Trials
